Although autoantibodies against p53α were detected in the HaloTag-based luminescence assays performed in this study, its seroreactivity in CRC patients did not differ greatly from healthy individuals, in contrast to other p53 and p63 proteoforms that were able to discriminate CRC patients from healthy individuals, with high sensitivity and specificity. This evidence concerns the gene TP53 and colorectal carcinoma.